MA52617A - Biomarqueurs sanguins de l'accident vasculaire cérébral - Google Patents

Biomarqueurs sanguins de l'accident vasculaire cérébral

Info

Publication number
MA52617A
MA52617A MA052617A MA52617A MA52617A MA 52617 A MA52617 A MA 52617A MA 052617 A MA052617 A MA 052617A MA 52617 A MA52617 A MA 52617A MA 52617 A MA52617 A MA 52617A
Authority
MA
Morocco
Prior art keywords
cerebral vascular
blood biomarkers
vascular accident
accident
biomarkers
Prior art date
Application number
MA052617A
Other languages
English (en)
French (fr)
Inventor
Emmanuelle Genin
Serge Timsit
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Francais Du Sang Ets
Inst Nat Sante Rech Med
Univ Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Francais Du Sang Ets, Inst Nat Sante Rech Med, Univ Bretagne Occidentale filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of MA52617A publication Critical patent/MA52617A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA052617A 2018-05-16 2019-05-16 Biomarqueurs sanguins de l'accident vasculaire cérébral MA52617A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16

Publications (1)

Publication Number Publication Date
MA52617A true MA52617A (fr) 2021-03-24

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052617A MA52617A (fr) 2018-05-16 2019-05-16 Biomarqueurs sanguins de l'accident vasculaire cérébral

Country Status (13)

Country Link
US (1) US12247257B2 (enExample)
EP (1) EP3794355A1 (enExample)
JP (2) JP7463351B2 (enExample)
KR (1) KR20210049026A (enExample)
CN (1) CN112424609A (enExample)
AU (1) AU2019270404B2 (enExample)
BR (1) BR112020023259A2 (enExample)
CA (1) CA3100171A1 (enExample)
IL (1) IL278666B2 (enExample)
MA (1) MA52617A (enExample)
MX (1) MX2020012297A (enExample)
SG (1) SG11202011369VA (enExample)
WO (1) WO2019219831A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
JP7861981B2 (ja) * 2022-01-31 2026-05-19 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
CN117925813A (zh) * 2023-11-27 2024-04-26 中国医学科学院药用植物研究所 缺血性卒中诊断模型和抗血小板药物的筛选方法
WO2025151599A1 (en) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Rna-based method for stroke assessment and treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO2003008647A2 (en) * 2000-11-28 2003-01-30 University Of Cincinnati Blood assessment of injury
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US9410204B2 (en) 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
EP2951318A4 (en) 2013-02-01 2016-08-17 Univ West Virginia BIOMARKER ALGORITHM FOR DETERMINING THE TIME OF INSERTING A STROKE SYMPTOM AND METHOD
WO2015054700A2 (en) * 2013-10-13 2015-04-16 The Research Foundation For Suny Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
GB2556004A (en) 2015-07-10 2018-05-16 Univ West Virginia Markers of stroke and stroke severity
US20190311789A1 (en) * 2016-10-03 2019-10-10 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Also Published As

Publication number Publication date
US20210214793A1 (en) 2021-07-15
KR20210049026A (ko) 2021-05-04
AU2019270404B2 (en) 2025-04-17
JP7463351B2 (ja) 2024-04-08
EP3794355A1 (en) 2021-03-24
IL278666B2 (en) 2025-06-01
MX2020012297A (es) 2021-03-25
AU2019270404A2 (en) 2020-12-17
IL278666A (en) 2020-12-31
CA3100171A1 (en) 2019-11-21
BR112020023259A2 (pt) 2021-02-23
US12247257B2 (en) 2025-03-11
SG11202011369VA (en) 2020-12-30
CN112424609A (zh) 2021-02-26
JP2021523744A (ja) 2021-09-09
AU2019270404A1 (en) 2020-12-10
IL278666B1 (en) 2025-02-01
JP2024075761A (ja) 2024-06-04
WO2019219831A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
EP3442612A4 (en) MEDIUM-TREATED BALLOON CATHETER FOR BODY LIQUIDS
EP4000540C0 (en) ACTUATED CLOT RECOVERY CATHETER
EP3917590C0 (en) VASCULAR CATHETER
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
IL288500A (en) Clot retrieval
IL288590A (en) Automatic prediction of blood infections
EP3471660A4 (en) MEDICAL DEVICE FOR THE TREATMENT OF VASCULATORS
EP3482201A4 (en) EARLY DIAGNOSIS OF INFECTIONS
IL280991A (en) Platelet count-agnostic methods of treating myelofibrosis
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
EP3936251A4 (en) VEHICLE BODY STRUCTURE
EP3803394A4 (en) CIRCULATORY BIOMARKERS FOR PLACENTAL OR FETAL HEALTH
EP3632431A4 (en) AGENTS FOR PREVENTING OR TREATING BRAIN ATROPHY
HUE062715T2 (hu) Eljárások perszonalizált véredények elõállítására
EP3471685A4 (en) EINWEG-PHIOLEN FOR THE ADMINISTRATION OF EYE DROPS
EP3641846A4 (en) HEMOFILTER FOR IN-VIVO BLOOD FILTRATION
EP3797816A4 (en) SAFETY CATHETER WITH REUSE PREVENTION
EP3551666A4 (en) VARIANTS OF ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND THEIR USES
EP3912890A4 (en) VEHICLE BODY STRUCTURE
EP4415796A4 (en) IMPROVED CEREBRAL ANGIOGRAPHY CATHETER
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
SI3794148T1 (sl) Postopki za diagnostiko anevrizme ali raka
EP3675715A4 (en) DETERMINATION STRATEGIES FOR EVALUATING THE CONDITION OF OSSEOINTEGRATED PROSTHESES
IT201700066486A1 (it) Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche